ABSTRACT
Although angiotensin-converting enzyme (ACE) inhibitors decrease mortality in heart failure, they incompletely suppress angiotensin II with long-term therapy. Since angiotensin receptor blockers (ARBs) block the biologic effects of angiotensin II more completely than ACE inhibitors, they could be beneficial in the treatment of heart failure.
Footnotes
↵* The author has indicated that he serves as a consultant for and is on the speakers’ bureau of the Astra-Zeneca corporation. This paper discusses therapies that are not approved by the US Food and Drug Administration for the use under discussion.
- Copyright © 2002 The Cleveland Clinic Foundation. All Rights Reserved.
